WHAT does some obscure "study" even have to do with BHRT? BHRT isn't even mentioned in it? It has nothing to do with them- let alone that it's something that's years and years away from a remote chance at an FDA approval or similar?
NO connection to BHRT that I can see?
Further, BHRT doesn't even hold patent or license to the "SDF-1" tech they were working with prior. It's right in their own recent 10-K SEC filing.
Most recent BHRT SEC filed 10-K, PAGE 6:
" Advancement of the MyoCell and MyoCell SDF-1 clinical development programs is contingent, among many factors, upon the Company obtaining access to sufficient funding to execute the necessary clinical trials to achieve proof of efficacy and regulatory authorization to market such products. The Company is also presently seeking a joint development partner for its MyoCell SDF-1 product candidate."
PAGE 11 (They HAD, PAST TENSE a license to SDF-1, now given to another company by the license holder)
"MyoCell SDF-1 Patents
To develop our MyoCell SDF-1 product candidate, we rely primarily on patents. We had an agreement to license patents from Juventas. These patents relate to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area. We believe we will also need to, among other things, license some additional intellectual property to commercialize MyoCell SDF-1 in the form we believe may prove to be the most safe and/or effective.
In February 2006, we signed a patent licensing agreement with the Cleveland Clinic which provided us with the worldwide, exclusive rights to three pending U.S. patent applications and certain corresponding foreign filings in the following jurisdictions: Australia, Brazil, Canada, China, Europe and Japan, or, collectively, the Cleveland Clinic IP, related to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area. The term of our agreement with the Cleveland Clinic expired in July of 2009, when the license to the patents was turned over to a Cleveland Clinic affiliate, Juventas. We have an understanding with Juventas to restore the license to the patents once certain milestones have been achieved by Bioheart.
In 2007, Bioheart signed a Letter of Intent with Ono Pharmaceutical which provided rights to conduct clinical development and testing of MyoCell SDF-1 to determine the effectiveness of MyoCell SDF-1 for the treatment of damaged myocardium and tissues following acute myocardial infarction, coronary arterial diseases or heart failure. If the results of this testing is deemed successful then the parties agree to enter into good faith negotiations in an effort to reach a definitive license agreement that will allow Bioheart to commercialize its MyoCell SDF-1 product candidate in all territories of the world except Japan."
2007, EIGHT YEARS ago. License went to JUVENTAS so BHRT doesn't even have rights to it anymore. The ole we have an "agreement" wording again? What does that even mean? A handshake? A note on the back of a napkin? What's an "agreement"- is it a legal contract in writing or what? BHRT doesn't even appear to have or own the rights to the SDF-1 technology it was pursuing YEARS AGO and has done nothing with since, it now being yr 2015.
What's some obscure link to something about some "SDF-1 whatever" got to do with BHRT?
I don't see any connection or relevance whatsoever? Not getting it IMO?
News 
Market Data 
Discover 
AI
